{
    "clinical_study": {
        "@rank": "111045", 
        "acronym": "MAGNIFY", 
        "arm_group": [
            {
                "arm_group_label": "Lenalidomide + rituximab followed by lenalidomide", 
                "arm_group_type": "Experimental", 
                "description": "Lenalidomide + rituximab (Induction & Maintenance) followed by lenalidomide (Maintenance)"
            }, 
            {
                "arm_group_label": "Lenalidomide + rituximab followed by rituximab", 
                "arm_group_type": "Active Comparator", 
                "description": "Lenalidomide + rituximab (Induction) followed by rituximab (Maintenance)"
            }
        ], 
        "brief_summary": {
            "textblock": "This Phase 3B multicenter, randomized (stratified by histology, lines of anti-lymphoma\n      therapy and age), open label study will enroll subjects with relapsed/refractory follicular\n      lymphoma (FL), marginal zone lymphoma (MZL) or mantle cell lymphoma (MZL). All subjects will\n      receive 12 Cycles of lenalidomide plus rituximab induction therapy. The study is designed to\n      compare the efficacy and safety of two maintenance regimens following induction therapy.\n      Subjects will be randomized at study start to lenalidomide plus rituximab combination\n      therapy (for 18 Cycles) followed by lenalidomide single-agent maintenance (to progression;\n      Arm A, experimental) versus rituximab single-agent maintenance (for 18 Cycles; Arm B,\n      control). The study is divided into a Screening Period, a Treatment Period (induction and\n      maintenance), and a Follow up Period. Approximately 500 subjects are planned to be\n      randomized."
        }, 
        "brief_title": "Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.", 
        "completion_date": {
            "#text": "October 2022", 
            "@type": "Anticipated"
        }, 
        "condition": "Lymphoma, Non-Hodgkin", 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin", 
                "Lymphoma, Mantle-Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "Follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL) are\n      cancers of  the B lymphocyte, a type of white blood cell. Lenalidomide is an\n      immunomodulatory drug (a drug that affects the immune system) which alters the body's immune\n      system and it may also interfere with the development of tiny blood vessels involved in\n      tumor growth.  Therefore, lenalidomide may reduce or prevent the growth of cancer cells.\n      Lenalidomide has also been shown to restore the immune cells' ability to attack and kill\n      tumor cells, an ability that may be inhibited by FL and other lymphomas. The combination of\n      rituximab and lenalidomide may eliminate the cancer while restoring the immune system's\n      ability to attack tumor cells.\n\n      Subjects must have an investigator assessed diagnosis of relapsed/refractory Grade 1, 2, or\n      3a follicular lymphoma (FL), marginal zone lymphoma (MZL), or mantle cell lymphoma (MCL),\n      Stage I to IV, have been previously treated for their lymphoma with at least one prior line\n      of systemic chemotherapy, immunotherapy, or chemoimmunotherapy;  have at least one\n      measurable nodal or extranodal lesion by computed axial tomography (CT) or magnetic\n      resonance imaging (MRI) scan, and have adequate bone marrow function, liver function, and\n      renal function.\n\n      Subjects with either follicular lymphoma (FL), marginal zone lymphoma (MZL), or mantle cell\n      lymphoma (MCL) will be randomized to Arm A will receive lenalidomide plus rituximab for up\n      to 30 Cycles (12 induction Cycles then 18 maintenance Cycles) followed by lenalidomide\n      single-agent maintenance (to disease progression [PD]).\n\n      Subjects with either follicular lymphoma (FL), marginal zone lymphoma (MZL), or mantle cell\n      lymphoma (MCL) will be randomized to Arm B will receive lenalidomide plus rituximab for 12\n      Cycles (induction) followed by rituximab single-agent for 18 Cycles (maintenance). Cycle\n      length in both arms is 28-days.\n\n      Efficacy determination for the primary endpoint will be based upon progression free survival\n      (PFS)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        -- Age \u226518 years\n\n          -  Histologically confirmed Follicular Lymphoma (Grade 1, 2 or 3a), Marginal Zone\n             Lymphoma, or Mantle Cell Lymphoma\n\n          -  Must have documented relapsed, refractory or Progressive Disease after last treatment\n             with systemic therapy\n\n          -  Bi-dimensionally measurable disease\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance status \u2264 2\n\n          -  Adequate bone marrow function\n\n          -  Willingness to follow pregnancy precautions\n\n        Exclusion Criteria:\n\n          -  Histology other than follicular or marginal zone lymphoma or clinical evidence of\n             transformation  or Grade 3b follicular lymphoma\n\n          -  Any medical condition (other than the underlying lymphoma) that requires chronic\n             steroid use\n\n          -  Subjects taking corticosteroids during the last 1 week prior treatment, unless\n             administered at a dose equivalent to < 20 mg/day of prednisone\n\n          -  Systemic anti-lymphoma therapy within 28 days or use of antibody agents within 8\n             weeks use of radioimmunotherapy within 3 months\n\n          -  Known seropositive for or active viral infection with hepatitis B virus (HBV),\n             hepatitis C virus (HCV), human immunodeficiency virus (HIV)\n\n          -  Known sensitivity or allergy to murine products\n\n          -  Presence or history of central nervous system involvement by lymphoma. Subjects who\n             are at a risk for a thromboembolic event and are not willing to take prophylaxis for\n             it.\n\n          -  Any condition that places the subject at unacceptable risk if he/she were to\n             participate in the study or that confounds the ability to interpret data from the\n             study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01996865", 
            "org_study_id": "CC-5013-NHL-008"
        }, 
        "intervention": [
            {
                "arm_group_label": "Lenalidomide + rituximab followed by lenalidomide", 
                "description": "Induction Period (12 Cycles) Lenalidomide 20 mg once daily on Days 1 to 21 of every 28-day Cycle Rrituximab 375 mg/m2 intra venous (IV) every week in Cycle 1 and Day 1 of every other Cycle.\nMaintenance Period (18 Cycles) Lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle Rrituximab 375 mg/m2 IV on Day 1 of every other Cycle.\nMaintenance Period (up to PD) Lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle", 
                "intervention_name": "Lenalidomide", 
                "intervention_type": "Drug", 
                "other_name": "CC-5013, Revlimid & Rituxan"
            }, 
            {
                "arm_group_label": "Lenalidomide + rituximab followed by lenalidomide", 
                "description": "Induction Period (12 Cycles) Lenalidomide 20 mg once daily on Days 1 to 21 of every 28-day Cycle Rrituximab 375 mg/m2 intra venous (IV) every week in Cycle 1 and Day 1 of every other Cycle.\nMaintenance Period (18 Cycles) Lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle Rrituximab 375 mg/m2 IV on Day 1 of every other Cycle.\nMaintenance Period (up to PD) Lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle", 
                "intervention_name": "Rituximab", 
                "intervention_type": "Drug", 
                "other_name": "CC-5013, Revlimid & Rituxan"
            }, 
            {
                "arm_group_label": "Lenalidomide + rituximab followed by rituximab", 
                "description": "Intervention Description:\nInduction Period (12 Cycles) Lenalidomide 20 mg once daily on Days 1 to 21 of every 28-day Cycle Rrituximab 375 mg/m2 intra venous (IV) every week in Cycle 1 and Day 1 of every other Cycle.\nMaintenance Period (18 Cycles) Lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle Rrituximab 375 mg/m2 IV on Day 1 of every other Cycle.\nMaintenance Period (up to PD) Lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle", 
                "intervention_name": "Lenalidomide", 
                "intervention_type": "Drug", 
                "other_name": "CC-5013, Revlimid & Rituxan"
            }, 
            {
                "arm_group_label": "Lenalidomide + rituximab followed by rituximab", 
                "description": "Induction Period (12 Cycles) Lenalidomide 20 mg once daily on Days 1 to 21 of every 28-day Cycle Rrituximab 375 mg/m2 intra venous (IV) every week in Cycle 1 and Day 1 of every other Cycle.\nMaintenance Period (18 Cycles) Lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle Rrituximab 375 mg/m2 IV on Day 1 of every other Cycle.\nMaintenance Period (up to PD) Lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle", 
                "intervention_name": "Rituximab", 
                "intervention_type": "Drug", 
                "other_name": "CC-5013, Revlimid & Rituxan"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Rituximab", 
                "Thalidomide", 
                "Lenalidomide"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Lymphoma, Mantle cell Lymphoma, Follicular Lymphoma, Marginal zone Lymphoma, Lenalidomide treatment, rituximab treatment, Non Hodgkins Lymphoma", 
        "lastchanged_date": "April 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Wenatchee", 
                    "country": "United States", 
                    "state": "Washington", 
                    "zip": "98801"
                }, 
                "name": "Wenatchee Valley Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-agent Maintenance Versus Rituximab Maintenance in Subjects With Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma", 
        "overall_contact": {
            "email": "clinicaltrialdisclosure@celgene.com", 
            "last_name": "Associate Director Clinical Trial Disclosure", 
            "phone": "1-888-260-1599"
        }, 
        "overall_contact_backup": {
            "email": "lvanwouwe@celgene.com", 
            "last_name": "Leon van Wouwe", 
            "phone": "+41 32 729 8814"
        }, 
        "overall_official": {
            "affiliation": "Celgene Corporation", 
            "last_name": "Kenneth Foon", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2021", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Progression free survival is defined as the time from randomization into the study to the first observation of documented disease progression or death due to any cause", 
            "measure": "Progression free survival (PFS) for Follicular lymphoma (FL), marginal zone lymphoma (MZL) and mantle cell lymphoma (MCL)", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 8 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01996865"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of participants with adverse events", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 8 years"
            }, 
            {
                "description": "Complete response rate is defined as proportion of subjects with a best response of at least unconfirmed complete remission (including complete remission and unconfirmed complete remission)", 
                "measure": "Complete response rate", 
                "safety_issue": "No", 
                "time_frame": "8 years"
            }, 
            {
                "description": "Overall response rate is defined as proportion of subjects with a best response of at least partial remission (including partial remission, complete remission and unconfirmed complete remission).", 
                "measure": "Overall response rate", 
                "safety_issue": "No", 
                "time_frame": "8 years"
            }, 
            {
                "description": "Duration of response is defined as the time from the initial response (at least partial remission) to documented disease progression", 
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "8 years"
            }, 
            {
                "description": "Duration of complete response is defined as the time from the first evidence of CR/CRu to documented disease progression", 
                "measure": "Duration of complete response", 
                "safety_issue": "No", 
                "time_frame": "8 years"
            }, 
            {
                "description": "Duration of response is defined as time from initial response of at least a PR to documented progression/relapse", 
                "measure": "Time to the next anti-lymphoma treatment", 
                "safety_issue": "No", 
                "time_frame": "8 years"
            }, 
            {
                "description": "Time to treatment failure is defined as the time from the date of randomization to discontinuation of treatment for any reason, including disease progression, treatment toxicity or death", 
                "measure": "Time to treatment failure", 
                "safety_issue": "No", 
                "time_frame": "8 years"
            }, 
            {
                "description": "Time to histological transformation is defined as the time from the date of randomization to time to histological transformation as measured based on documentation of histological transformation", 
                "measure": "Time to histological transformation", 
                "safety_issue": "No", 
                "time_frame": "8 years"
            }
        ], 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}